Discovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type 1 diabetes
Smyth, Deborah J
Healy, Barry C
Lam, Alex C
Walker, Neil M
Smink, Luc J
MetadataShow full item record
Taniguchi, H., Lowe, C., Cooper, J., Smyth, D. J., Bailey, R., Nutland, S., Healy, B. C., et al. (2006). Discovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type 1 diabetes. https://doi.org/10.1186/1471-2156-7-22
Abstract Background Type 1 diabetes (T1D) is a common autoimmune disease resulting from T-cell mediated destruction of pancreatic beta cells. Decay accelerating factor (DAF, CD55), a glycosylphosphatidylinositol-anchored membrane protein, is a candidate for autoimmune disease susceptibility based on its role in restricting complement activation and evidence that DAF expression modulates the phenotype of mice models for autoimmune disease. In this study, we adopt a linkage disequilibrium (LD) mapping approach to test for an association between the DAF gene and T1D. Results Initially, we used HapMap II genotype data to examine LD across the DAF region. Additional resequencing was required, identifying 16 novel polymorphisms. Combining both datasets, a LD mapping approach was adopted to test for association with T1D. Seven tag SNPs were selected and genotyped in case-control (3,523 cases and 3,817 controls) and family (725 families) collections. Conclusion We obtained no evidence of association between T1D and the DAF region in two independent collections. In addition, we assessed the impact of using only HapMap II genotypes for the selection of tag SNPs and, based on this study, found that HapMap II genotypes may require additional SNP discovery for comprehensive LD mapping of some genes in common disease.
External DOI: https://doi.org/10.1186/1471-2156-7-22
This record's URL: http://www.dspace.cam.ac.uk/handle/1810/238067
Rights Holder: Taniguchi et al.; licensee BioMed Central Ltd.